Committee for Medicinal Products for Human Use


Also found in: Acronyms, Wikipedia.

Committee for Medicinal Products for Human Use

The European Medicines Agency's committee, which is responsible for elaborating the agency's opinions on all issues regarding medicinal products for human use.
References in periodicals archive ?
NYSE:ACL) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the initial marketing authorization for DuoTrav(TM) solution (travoprost 0.
GTC", Nasdaq: GTCB) announced today that it has been told that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) intends to issue a negative opinion on the market authorization application (MAA) for ATryn(R), GTC's recombinant form of human antithrombin.
Originally the Agency's scientific committee, the Committee for Medicinal Products for Human Use (CHMP), was expected to formally adopt an opinion at their meeting of March 20-23, 2006.
GTC does not expect to have any new announcement regarding its ATryn(R) submission to the European Medicines Agency before the conclusion of the meeting of the Committee for Medicinal Products for Human Use (CHMP) which takes place from February 20 through February 23.
GTC", Nasdaq: GTCB) announced today that it has received a $1 million payment from LEO Pharma A/S for achieving the milestone of a positive opinion on the market authorization application for ATryn(R) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA).
LONDON -- Bioenvision (Nasdaq:BIVN) today announced that an Oral Explanation before the Committee for Medicinal Products for Human Use (CHMP) has been scheduled for the week commencing February 20th 2006, in relation to the European Marketing Authorization Application (MAA) for clofarabine in the treatment of patients (up to 21 years old at initial diagnosis) with relapsed or refractory acute lymphoblastic leukemia (ALL) after at least two prior regimens.
AVANT Immunotherapeutics (Nasdaq: AVAN) today announced that its partner GlaxoSmithKline (GSK) Biologicals has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Rotarix(R) rotavirus vaccine.
NASDAQ: OSIP) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has advised Pfizer Inc, (OSI) Eyetech's international marketing partner for Macugen(R)(pegaptanib sodium injection), that it will issue an updated positive opinion recommending approval of Macugen for the treatment of neovascular (wet) age-related macular degeneration (neovascular AMD).
On October 29 and 30, the meetings of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency and the Informal Pharmacovigilance Risk Assessment Committee (PRAC) will take place in Vilnius.
Full browser ?